Celldex Therapeutics reported $436.71M in Equity Capital and Reserves for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Amgen AMGN:US $ 8217M 30M
Applied Genetic Technologies AGTC:US $ 69.53M 16.28M
Aptinyx Inc APTX:US $ 112.04M 18.71M
Arena Pharmaceuticals ARNA:US $ 800.72M 170.36M
Biocept BIOC:US $ 40.06M 10.7M
Bristol Myers Squibb BMY:US $ 37213M 405M
Celldex Therapeutics CLDX:US $ 436.71M 254.43M
Cytrx CYTR:US 9.95M 3.46M
Glaxosmithkline GSK:US $ 15426M 49M
Immunogen IMGN:US $ 77.09M 8.63M
Merrimack Pharmaceuticals MACK:US $ 16.01M 734K
Nektar Therapeutics NKTR:US $ 801.54M 103.44M
Newlink Genetics NLNK:US $ 94.12M 7M
Northwest Biotherapeutics NWBO:US -301733000 48.11M
Rigel Pharmaceuticals RIGL:US $ 49.67M 18.44M
Seattle Genetics SGEN:US $ 3164.96M 226.32M